Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin e monoclonal antibody, in healthy Chinese subjects

mAbs

Volumn 4, Issue 1, 2012, Pages 110-119

  Zhou, Bo ^a,b,c   Lin, Birong ^b   Li, Jing ^a,b,c   Qian, Weizhu ^a,b,c   Hou, Sheng ^a,b,c   Zhang, Dapeng ^a,b,c   Kou, Geng ^a,b,c   Li, Bohua ^a,b,c   Wang, Hao ^a,b,c   Chen, Yongchuan ^d   Guo, Yajun ^a,b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b National Engineering Research Center of Antibody Medicine   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Humanized antibody; IgE; Pharmacodynamics; Pharmacokinetics; Safety

Indexed keywords

CMAB 007; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SINUS TACHYCARDIA; STEADY STATE; THORAX RADIOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CHINA; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN E; INJECTIONS, SUBCUTANEOUS; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863063178     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.4.1.18349     Document Type: Article

References (19)

1. Ishizaka T, Ishizaka K. Activation of mast cells for mediator release through IgE receptors. Prog Allergy 1984; 34:188-235; PMID:6199797.
2. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151:2623-32; PMID:8360482.
3. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100:110-21; PMID:9257795; http://dx.doi.org/10.1016/S0091-6749(97)70202-1.
4. Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009; 123:107-13; PMID:19130931; http://dx.doi.org/10.1016/j.jaci.2008.09.050.
5. Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003; 19:491-8; PMID:14594521; http://dx.doi.org/10.1185/030079903125002171.
6. Genentech, Inc., Xolair® (omalizumab for subcutaneous use) label. Available at www.accessdata.fda.gov/drugsatfda-docs/label/2007/103976s5102lbl. pdf. (29 Sep 2011, date last accessed).
7. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest 1970; 49:673-80; PMID:5443170; http://dx.doi.org/10.1172/ JCI106279.
8. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29:310-2; PMID:21478841; http://dx.doi.org/10.1038/nbt.1839.
9. Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006; 21:13-6; PMID:16959789; http://dx.doi.org/10.1093/ndt/gfl475.
10. Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005; 45:792-801; PMID:15951469; http://dx.doi.org/10.1177/0091270005277075.
11. Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006; 23:1275-84; PMID:16715358; http://dx.doi.org/10.1007/s11095-006- 0205-x.
12. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62:779-86; PMID:18205003; http://dx.doi.org/10.1007/s00280-007- 0664-8.
13. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25:1700-21; PMID:12860493; http://dx.doi.org/10.1016/S0149-2918(03) 80164-9.
14. Froehlich J, Schoenhoff M, Tremblay T, Ruppel J, Jardieu P. Initial human study with a humanized recombinant anti-IgE monoclonal antibody: safety, tolerance and pharmacokinetic (PK)/dynamic profile. Clin Pharmacol Ther 1995; 57:162.
15. Putnam WS, Prabhu S, Zheng Y, Subramanyam M, Wang YM. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol 2010; 28:509-16; PMID:20691488; http://dx.doi.org/10.1016/j.tibtech.2010.07.001.
16. Covic A, Cannata-Andia J, Cancarini G, Coppo R, Frazão JM, Goldsmith D, et al. Biosimilars and biopharmaceuticals: what the nephrologists need to know - a position paper by the ERA-EDTA Council. Nephrol Dial Transplant 2008; 23:3731-7; PMID:18802209; http://dx.doi.org/10.1093/ndt/gfn519.
17. Li J, Li X, Tan M, Lin B, Hou S, Qian W, et al. Two doses of humanized anti-CD25 antibody in renal transplantation: a preliminary comparative study. mAbs 2009; 1:49-55; PMID:20046574; http://dx.doi.org/10.4161/mabs.1.1.7399.
18. European Medicines Agency. Valtropin: scientific discussion 2007. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Scientific- Discussion/human/000602/WC500047158.pdf. (29 Sep 2011, date last accessed).
19. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007; 63:548-61; PMID:17096680; http://dx.doi.org/10.1111/j. 1365-2125.2006.02803.x.